Cover Image
市場調查報告書

同合子家族性高膽固醇血症 (HoFH) :開發中產品分析

Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 361615
出版日期 內容資訊 英文 71 Pages
訂單完成後即時交付
價格
Back to Top
同合子家族性高膽固醇血症 (HoFH) :開發中產品分析 Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H1 2016
出版日期: 2016年05月31日 內容資訊: 英文 71 Pages
簡介

本報告提供同合子家族性高膽固醇血症 (HoFH) 的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

同合子家族性高膽固醇血症 (HoFH)概要

治療藥的開發

  • 開發中產品的概要

同合子家族性高膽固醇血症 (HoFH):企業開發中的治療藥

同合子家族性高膽固醇血症 (HoFH):開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

同合子家族性高膽固醇血症 (HoFH):企業開發中的產品

同合子家族性高膽固醇血症 (HoFH的)治療藥的開發企業

  • Aegerion Pharmaceuticals, Inc.
  • CymaBay Therapeutics, Inc.
  • Kastle Therapeutics LLC
  • Regeneron Pharmaceuticals, Inc.
  • RegenxBio Inc.

同合子家族性高膽固醇血症 (HoFH):治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

同合子家族性高膽固醇血症 (HoFH):最近的開發平台趨勢

同合子家族性高膽固醇血症 (HoFH):暫停中的計劃

同合子家族性高膽固醇血症 (HoFH):產品開發的里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC8110IDB

Summary

Global Markets Direct's, 'Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H1 2016', provides an overview of the Homozygous Familial Hypercholesterolemia (HoFH) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Homozygous Familial Hypercholesterolemia (HoFH), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Homozygous Familial Hypercholesterolemia (HoFH) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Homozygous Familial Hypercholesterolemia (HoFH)
  • The report reviews pipeline therapeutics for Homozygous Familial Hypercholesterolemia (HoFH) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Homozygous Familial Hypercholesterolemia (HoFH) therapeutics and enlists all their major and minor projects
  • The report assesses Homozygous Familial Hypercholesterolemia (HoFH) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Homozygous Familial Hypercholesterolemia (HoFH)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Homozygous Familial Hypercholesterolemia (HoFH)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Homozygous Familial Hypercholesterolemia (HoFH) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Homozygous Familial Hypercholesterolemia (HoFH) Overview
  • Therapeutics Development
    • Pipeline Products for Homozygous Familial Hypercholesterolemia (HoFH) - Overview
  • Homozygous Familial Hypercholesterolemia (HoFH) - Therapeutics under Development by Companies
  • Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Homozygous Familial Hypercholesterolemia (HoFH) - Products under Development by Companies
  • Homozygous Familial Hypercholesterolemia (HoFH) - Companies Involved in Therapeutics Development
    • Aegerion Pharmaceuticals, Inc.
    • CymaBay Therapeutics, Inc.
    • Kastle Therapeutics LLC
    • Regeneron Pharmaceuticals, Inc.
    • RegenxBio Inc.
  • Homozygous Familial Hypercholesterolemia (HoFH) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AEM-28 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AEM-2802 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AEM-2814 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AM-0010 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • evinacumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • gemcabene calcium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lomitapide mesylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MBX-8025 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MGL-3196 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MGL-3745 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mipomersen sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RGX-501 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Homozygous Familial Hypercholesterolemia (HoFH) - Recent Pipeline Updates
  • Homozygous Familial Hypercholesterolemia (HoFH) - Dormant Projects
  • Homozygous Familial Hypercholesterolemia (HoFH) - Product Development Milestones
    • Featured News & Press Releases
      • Mar 17, 2016: CymaBay Therapeutics Announces Positive Results from its Pilot Phase 2 Clinical Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia
      • Nov 20, 2015: JUXTAPID (lomitapide) Capsules Available on the Regie de l'Assurance Maladie du Quebec (RAMQ) for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
      • Nov 10, 2015: Aegerion Pharmaceuticals Announces Results From First Year of LOWER Study at AHA Scientific Sessions 2015
      • May 26, 2015: Aegerion Pharmaceuticals Achieves Primary Endpoint in Phase III Study of Lomitapide in Japanese Patients With Homozygous Familial Hypercholesterolemia (HoFH)
      • Apr 30, 2015: AOP Orphan Launches Lojuxta (lomitapide) for Treatment of Homozygous Familial Hypercholesterolaemia to the Austrian Market
      • Apr 23, 2015: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Homozygous Familial Hypercholesterolemia
      • Mar 25, 2015: CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Homozygous Familial Hypercholesterolemia
      • Jan 28, 2015: Aegerion Investigated by Former Louisiana Attorney General and Special Prosecutor Richard P. Ieyoub and the Firm of Ieyoub O'Bell & Myers
      • Aug 27, 2014: Aegerion Pharmaceuticals Announces Resolution of Warning Letter for JUXTAPID Capsules
      • Apr 09, 2014: Aegerion Pharmaceuticals Initiates Phase 3 Clinical Trial in Japan to Evaluate Lomitapide for Treatment of Homozygous Familial Hypercholesterolemia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Homozygous Familial Hypercholesterolemia (HoFH), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline by Aegerion Pharmaceuticals, Inc., H1 2016
  • Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline by CymaBay Therapeutics, Inc., H1 2016
  • Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline by Kastle Therapeutics LLC, H1 2016
  • Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016
  • Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline by RegenxBio Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics - Recent Pipeline Updates, H1 2016
  • Homozygous Familial Hypercholesterolemia (HoFH) - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Homozygous Familial Hypercholesterolemia (HoFH), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top